$LQDA

Bloch Stephen M sold $6.3M of LQDA (indirect holdings)

Bloch Stephen M sold 78,596 indirectly-held shares of Liquidia Corp (LQDA) at an average of $79.97 ($79.55–$80.66, $6.29M total) across 3 trades over 2026-07-20 to 2026-07-21.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jul 22, 2026, 11:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 22, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The only new information is the disclosed sale details (shares, price range, total value, post-transaction holdings).

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not provide a new fundamental catalyst.

03

What to watch

The article notes no 10b5-1 plan, but it does not provide the director’s broader holdings, tax/liquidity needs, or whether other insiders made offsetting purchases.

Relevance 6/10Novelty 3/10Timing: new SEC Form 4 filed 2026-07-22 for sales executed 2026-07-20 to 2026-07-21

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Liquidia Corp.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia director Stephen M. Bloch sold 78,596 shares in open-market trades for about $6.29M, per a new SEC Form 4 filing.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than based on new company performance data.

Evidence & confidence

The filing discloses transaction size, dates, and price range, but provides no new operational, regulatory, or financial catalyst for Liquidia.

Market effects

Minimal; insider sale in a single biotech does not imply sector-wide changes.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity events and may not reflect bearish expectations, especially without any accompanying negative company news.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure (LQDA).

  • Bloch Stephen M

    Director who sold shares via open-market transactions; indirect holdings reported.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.